PARP Inhibitor Combination Approaches in Prostate Cancer: Interpretation of Clinical Findings and Regulatory Approvals

Expert insight on integrating PARP inhibitor combination therapy into clinical practice for patients with prostate cancer including a downloadable slideset, interactive webcast, and expert commentary.

Share

Program Content

Activities

PARPi Monotherapy in PCa
Single-Agent PARP Inhibitors in Prostate Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 24, 2024

View Activity
Rationale for PARP Combos in PCa
Leveraging Interdependencies of Targeted Pathways: Rationale for PARPi Combinations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 24, 2024

View Activity
PARPi Combinations in PCa
PARP Inhibitor/AR Pathway Inhibitor Combination Approaches in Prostate Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 24, 2024

View Activity

Activities

PARPi in Prostate Cancer
Clinical Findings and Approvals: PARP Inhibitor Strategies in Prostate Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 07, 2024

Expires: February 06, 2025

View Activity

Activities

PARPi in Prostate Cancer
Understanding the Role of PARP Inhibitors in Prostate Cancer: Key Takeaways From a Symposium in San Francisco
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 12, 2024

View Activity

Faculty

cover img faculity

Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

cover img faculity

Neeraj Agarwal, MD

Professor of Medicine
Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

cover img faculity

Andrew Armstrong, MD, ScM, FACP

Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research
The Duke Cancer Institute Center for Prostate and Urologic Cancers
Divisions of Medical Oncology and Urology
Duke University
Durham, North Carolina

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc., Rahway, NJ, USA